This is a Phase 3, randomized, double-blind, placebo-controlled study
evaluating the safety and efficacy of GS-9674 in subjects with PSC
The study will consist of an 8-week Screening period,96 weeks of treatment, and a follow-up visit 4 weeks after completion of treatment. (Patients would be required to come to MUSC for 12 visits for a physical check-up, blood work, and to receive more study medication).
If the subject qualifies they will be randomized into one of two groups. The two groups include one receiving 100mg active GS-9674 or placebo. There is a 2/3 chance to be receiving active drug over placebo. The drug GS-9674 is a capsule that is taken once a day in the morning (with or without food).
The purpose of this study is to see if GS-9674 slows the scarring process in subjects with PSC.
The purpose of this study is to see if Rifaximin Soluble Solid Dispersion (SSD) Tablets are safe, well-tolerated, and whether they can better treat overt hepatic encephalopathy, a complication associated with liver cirrhosis, when compared to a placebo (an inactive substance).
This is a clinical research study of an investigational new drug that is being developed as a possible treatment in patients with hepatic insufficiency, cirrhosis and or/elevated blood ammonia levels. Ammonia is a substance that is built during the breakdown of the proteins in blood; in case of errors in the breakdown of proteins, ammonia levels might increase. Elevated ammonia may lead to other medical conditions. The study will help to determine the safety and tolerability of the study medication in male and female patients; in addition, the study investigates the study medications pharmacokinetics and pharmacodynamics.
This study is an inpatient study.
This study consists of 2 parts (part 1 and part 2). However our institution will only be taking part in part 2 of the study (described below) because recruitment for part one has been closed (as indicated by our sponsors).
Patients will initially present for a screening visit where eligibility will be determined. If patients are eligible for this study they will be admitted to an inpatient unit for a total of 12 days. During the 12 days of hospital stay, patients will receive study drug/placebo, regulated diet (predetermined as per study protocol) and several blood tests will be withdrawn measuring serum ammonia levels during this hospital stay. Once patients are discharged from hospital stay, they will be expected to follow up 1 week and 70 days after last study drug/placebo was administered (i.e last day in the hospital) with a stool sample.
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
This an observational study that aims to assess the outcome of patients with advanced fibrosis and cirrhosis recurrence in patients with hepatitis C virus (HCV) infection after HCV eradication. We aim to describe this unique group of patients as well as determine whether any particular variables are significant predictors of fibrosis/cirrhosis resolution. A multivariate analysis will be conducted to determine risk factors independently related to fibrosis/cirrhosis resolution and clinical outcome.
The purpose of this study is to confirm the efficacy and safety of terlipressin in the treatment of adult subjects admitted to the hospital with hepatorenal syndrome (HRS) Type 1. Hepatorenal syndrome Type 1 is a severe, but potentially reversible, form of renal failure that afflicts patients with severe chronic liver disease associated with cirrhosis. This will be a randomized, placebo-controlled, and double-blinded multi-center study. Patients will be randomly be placed in either a terlipressin-treatment group or a placebo group. Neither you nor the study team will know which group you have been placed in. The study drug will be given as an IV injection every 6 hours while the patient is an inpatient at the hospital every 6 hours. This is a phase 3 study, with prior studies already showing promising results.
This is a treatment study for people who have Nonalcoholic Steatohepatitis (NASH) fibrosis but not cirrhosis. The purpose of the study is to see whether the oral investigational medication, Elafibranor, is effective and safe in treating liver fibrosis.
The study will compare two durations of treatment with Octreotide in patients with confirmed esophageal variceal hemorrhage who have undergone successful endoscopy and possible endoscopic therapy for control of bleeding. All procedures including the treatment are the standard of care. Octreotide infusion and endoscopic therapy for esophageal variceal bleeding are not investigational.
This study is to find the best time that a follow up appointment can be scheduled to benefit the patient with liver cirrohis to return after having the bleeding vessels in the esophagus repaired by directing a scope in the esophagus and using bands to stop the bleeding.